King Faisal Specialist Hospital & Research Centre

King Faisal Specialist Hospital and Research Center

Khalid S Abu Khabar

Nora Al-Souhibani

Asma Tulbah

Tala Bakheet

Edward Hitti

Taher Twegieri

Adher Alsayed

Adher Al Sayed

The present invention relates to a method of determining if a patient is likely to respond to a treatment with a targeted therapy compound selected from protein kinase inhibitors, small molecule inhibitors, and monoclonal antibody-based compounds. The present invention further relates to a method of identifying a targeted therapy compound selected from protein kinase inhibitors, small molecule inhibitors, and monoclonal antibody-based compounds for personalized medicine. The present invention also relates to a method of treatment of cancer in a patient. The present invention also relates to a targeted therapy compound selected from protein kinase inhibitors, small molecule inhibitors, and monoclonal antibody-based compounds for use in a method of treatment of cancer in a patient.

TTP phosphorylation for the identification of personalized medicines

The present invention relates to a set of genes for use in a method of predicting the likelihood of a breast cancer patient's survival or of predicting the likelihood of a recurrence and/or aggressiveness of a breast cancer in a breast cancer patient. The present invention also relates to a method for predicting the likelihood of a breast cancer patient's survival or the likelihood of the recurrence or aggressiveness of a breast cancer in a breast cancer patient, as well as to a kit for use in such method.

Set of genes for use in a method of predicting the likelihood of a breast cancer patient's survival

TTP phosphorylation as a biomarker in targeted therapy

The present invention relates to fluorescent proteins, in particular green fluorescent proteins (GFPs), with increased activity in cells, and thus increased signal strength. A further aspect of the present invention relates to the use of peptides for increasing the expression and/or stability of a protein in a cell.

Method for increasing the expression and/or stability of a protein in a cell and a peptide for use in such method

The present invention describes the use of hybrid short 3' untranslated (3&#x2032;UTR) regions which are composed of two regions, one region from an 3&#x2032; untranslated region of a stable eukaryotic mRNA, and another region from the downstream end of an 3&#x2032; untranslated region of another eukaryotic mRNA that contains a polyadenylation (polyA) signal. The use of such hybrid regions allows for an efficient protein expression when used in conjunction with circular or linear expression DNA molecules. The present invention provides a recombinant DNA that is composed of a promoter, a protein coding region, and the hybrid 3&#x2032;UTR in a continuous and directional orientation. The efficient expression systems of the invention are suitable for the economical and efficient production of therapeutic proteins and for use with both transient and stable expression systems.

Hybrid 3' untranslated regions suitable for efficient protein expression in mammalian cells

The present invention relates to expression vector comprising (a) a promoter region comprising a non-inducible constitutively active ribosomal protein gene promoter, (b) an operably linked reporter or gene sequence, and (c) a 3' untranslated region (3&#x2032; UTR), which are suitable means for an selective assessment of post-transcriptional regulation, post-transcriptional control elements and factors as well as for identifying compounds that effect post-transcription. The present invention furthermore relates to arrays, expression vector libraries and cell lines containing the expression vector(s). The present invention furthermore relates to a method and kit for identifying compounds that affect post-transcriptional regulation of reporter(s) or gene(s), that utilize the expression vector(s).

Expression vectors based on modified ribosomal protein promoters and uses thereof in post-transcriptional assessment

Fluorescent proteins with increased activity in cells

The present invention relates to a (first) method for producing inducible and/or repressible expression active linear RNA interference constructs comprising a PCR amplification of a source polynucleotide comprising the inhibitory RNA coding sequence of interest or comprising a PCR amplification of a DNA source comprising a promoter using a reverse primer comprising the inhibitory RNA coding sequence of interest. The present invention furthermore relates to a (second) method for producing inducible and/or repressible expression active linear gene constructs comprising a PCR amplification of a source expression polynucleotide comprising a promoter sequence and the DNA sequence of interest or comprising a PCR amplification using the DNA sequence as a template. The present invention furthermore relates to libraries, arrays, cells and cell lines and kits utilizing the inducible and/or repressible expression active linear RNA interference constructs or the inducible and/or repressible expression active linear gene constructs.

Methods for producing inducible and/or repressible expression active linear RNA interference cassettes and inducible and/or repressible expression active linear gene cassettes and their uses

Growing community of inventors

Riyadh, Saudi Arabia

Khalid S Abu Khabar